Biomaterials

Biomaterials are materials designed to sit inside or against the living body and do a job there: replace a hip joint, hold a wound closed, scaffold new tissue, deliver a drug, or quietly disappear once the body has healed.

9 frameworks, from 1940 to today · Materials Science · Natural Sciences

still a working view ended · each leads to its entry below

Overview

Biomaterials are materials designed to sit inside or against the living body and do a job there: replace a hip joint, hold a wound closed, scaffold new tissue, deliver a drug, or quietly disappear once the body has healed1. The field sits where materials science meets medicine, and its central problem is unlike almost any other in engineering1. A bridge girder must resist weather; an implant must resist a body that is actively trying to dissolve, encapsulate, or reject it, while the body itself must not be poisoned or chronically inflamed by the material. What makes the history interesting is that the definition of success kept shifting. Early practitioners asked whether a material could survive the body without doing harm. Later ones asked whether the body could be persuaded to accept, or even rebuild itself around, the material. Today many ask whether the material can steer the immune system deliberately. Each shift came from a failure the previous approach could not explain.

Metals, Sutures, and the First Implants

Repairing the body with foreign materials is ancient. Archaeological finds include gold dental wire and, from roughly the first millennium BCE, sutures of linen, hair, and gut; the Roman writer Galen described gladiators' tendon repairs. But the modern field begins with the industrial production of metals and sterile surgery in the nineteenth and early twentieth centuries. Bone plates of iron and later steel were tried for fractures in the late 1800s, often failing through corrosion and infection. The decisive material was stainless steel: the "18-8" austenitic alloy (roughly 18% chromium, 8% nickel) developed in Germany before the First World War, and its surgical variant, which came to be known as 316L, became the workhorse of orthopaedics. Its chromium-rich surface oxide layer, a few atoms thick, passivates the metal—seals it against further reaction—so it corrodes only slowly in body fluid2.

The mid-twentieth century brought the era now called inert biomaterials: substances chosen to provoke as little reaction as possible. Titanium and its alloys, whose oxide layer makes them unusually well tolerated by bone, entered orthopaedics in the 1940s and 1950s; the polymethyl methacrylate bone cement used to fix hip implants was adapted from dentistry in the late 1950s, and the total hip replacement pioneered by John Charnley in England around 1962 combined a stainless-steel stem, a polyethylene socket, and acrylic cement into a procedure that transformed millions of lives. The guiding belief was "minimal interaction": the best material is one the body ignores. That belief was productive but incomplete, and the failures it produced drove the next phase.

Retrieval and the Anatomy of Failure

Implants that seemed fine in the operating theatre sometimes loosened, discoloured, or killed the surrounding bone years later. The response was a discipline of retrieval and failure analysis: systematically recovering explanted devices and examining them with the tools of metallurgy and pathology. Work at institutions such as the Cleveland Clinic and later dedicated implant retrieval laboratories in the 1970s and 1980s showed that "inert" was a fiction. Metal ions leached; wear particles from polyethylene sockets triggered a foreign-body reaction in which immune cells called macrophages, frustrated at being unable to digest the particles, released signalling molecules that activated bone-resorbing cells (osteoclasts), loosening the implant—a process known as particle disease or osteolysis. Retrieval studies taught the field that the body's response, not just the material's bulk properties, determines whether a device lasts. This reframing set up everything that followed.

The Surface Is the Interface

If the body reacts to the material's surface rather than its interior, then surface science becomes central. When an implant enters the body, it is coated within seconds by a layer of adsorbed proteins from blood and tissue fluid—albumin, fibrinogen, immunoglobulins, and others—and cells actually "see" this protein film, not the bare material. Research from the 1960s onward, drawing on the physical chemistry of adsorption, established that the composition, charge, and wettability of a surface determine which proteins stick and in what conformation, and therefore whether platelets clump (clotting) or cells spread and adhere. A landmark concept from the 1980s, the Vroman effect, described how proteins compete for a surface over time, with abundant but weakly bound proteins displaced by scarcer ones with higher affinity. This understanding made surface modification a design tool: coatings, chemical grafts, and texturing to control protein adsorption and hence clotting, infection, and tissue integration.

Bioactive Materials: Making the Body Respond

The next turning point inverted the goal. Instead of hiding from the body, a material could chemically bond to it. The key discovery was Bioglass, a soda–lime–phosphosilicate glass developed by Larry Hench and colleagues at the University of Florida and reported in 1971. Implanted in bone, certain compositions of this glass dissolve slightly at the surface and precipitate a layer of hydroxycarbonate apatite—chemically close to bone mineral—which living bone then bonds to directly, without the fibrous scar capsule that forms around inert implants. The mechanism was a controlled surface reaction, and it showed that a synthetic material could be bioactive: provoke a specific, beneficial biological response. A parallel line of work produced calcium phosphate ceramics, notably hydroxyapatite, used as bone-graft substitutes from the 1970s and 1980s. Bioactive materials reframed the implant as a participant in healing rather than a passive guest.

Polymers That Dissolve: Sutures, Screws, and Drug Carriers

Meanwhile, a different class of materials was being developed: resorbable polymers, which break down in the body into harmless products and are eventually eliminated1. The best-known is poly(lactic-co-glycolic acid), or PLGA, a copolymer of lactic and glycolic acid whose degradation rate can be tuned by changing the ratio of the two components; it hydrolyses into lactic and glycolic acid, which enter normal metabolism. Absorbable sutures based on related polyesters (polyglycolic acid under the trade name Dexon, introduced in the early 1970s) removed the need for a second operation to take stitches out. The same chemistry became the backbone of controlled drug delivery: polymer microspheres and implants that release a drug slowly over weeks or months, an approach advanced by Robert Langer and Judah Folkman's work on macromolecule release in the mid-1970s and commercialised in products such as the leuprolide-releasing implant Lupron Depot in the late 1980s. Resorbable polymers made the implant temporary by design—a profound change in what a biomaterial could be.

Tissue Engineering and the Scaffold

By the 1980s the ambition grew larger: rather than replace tissue, regrow it. The term tissue engineering was formalised at a landmark 1988 meeting sponsored by the US National Science Foundation, and the field's founding statement is often dated to a 1993 paper by Langer and Joseph Vacanti in Science. The central object is the scaffold: a porous, often resorbable structure that mimics the extracellular matrix—the mesh of proteins and polysaccharides that holds cells in living tissue—providing mechanical support and physical cues while cells migrate in, multiply, and lay down their own matrix as the scaffold degrades13. Early successes included skin substitutes and cartilage constructs; a widely cited demonstration was the 1990s engineering of a functioning bladder by Anthony Atala's group, reported in 2006, in which patients' own cells were grown on a biodegradable scaffold. Scaffold design became a discipline in itself, balancing pore size (large enough for cells and blood vessels to penetrate), degradation rate (matched to the rate of new tissue formation), and stiffness.

Biodegradable Metals and the Corrosion That Heals

A newer twist on resorption concerns metals. Magnesium and its alloys corrode in the body, releasing magnesium ions the body handles routinely, and were tried as implant metals as early as the late nineteenth century—but too fast, producing hydrogen gas bubbles and losing strength before bone healed. Modern biodegradable metals research, accelerating from the 2000s, engineered alloys and coatings to slow corrosion to a useful rate, so that a magnesium screw can hold a fracture while it heals and then vanish, avoiding a removal operation. Iron and zinc alloys followed as alternatives with different corrosion profiles. The concept is elegant but demanding: the corrosion rate must be matched to healing, and the local chemistry of degradation must be benign.

Printing the Implant

Additive manufacturing—building objects layer by layer from a digital model—entered biomaterials from the 1990s and became transformative in the 2000s and 2010s. Techniques such as selective laser melting of titanium allowed implants with porous, bone-like lattice structures that encourage bone ingrowth and match a patient's anatomy from a CT scan; extrusion-based printing of polymers and hydrogels allowed scaffolds with precisely controlled pore architecture and even the printing of cells themselves (bioprinting). The method solved a problem conventional manufacturing could not: making complex, patient-specific, internally porous structures economically, and controlling scaffold geometry at the scale of cells.

Steering the Immune System

The most recent reframing grows directly from the retrieval lessons. The immune system is not merely an obstacle to be evaded; it is a participant that can be directed. Immunomodulatory biomaterials aim to shape the response—for instance, promoting a "pro-healing" macrophage state rather than the inflammatory one that causes fibrosis and implant rejection, or using materials as vaccine adjuvants or to induce tolerance. Research from the 2010s onward showed that physical and chemical properties of a material—its stiffness, its surface chemistry, the size and shape of its particles—can bias immune cells toward healing or inflammation. This closes a loop with the earliest retrieval studies: the field now designs deliberately for the biological response it once merely observed.

Where the Field Stands

Today biomaterials research runs along all these lines at once. Metals remain dominant in load-bearing orthopaedics, now often additively manufactured and surface-engineered; bioactive glasses and ceramics anchor bone regeneration; resorbable polyesters underpin sutures, drug delivery, and scaffolds; hydrogels—water-swollen polymer networks—dominate soft-tissue and cell-based work; and biodegradable metals are moving through clinical trials. The open questions are substantial: matching degradation to healing in every patient, achieving long-term integration without fibrosis, manufacturing patient-specific devices at acceptable cost, and understanding and controlling the immune response well enough to make "pro-healing" a reliable design specification rather than a laboratory observation. The history's pattern—each era defined by a failure the previous definition of success could not accommodate—suggests the field's ambitions will keep outrunning its materials.

References

  1. Biomaterial (introduction, Introduction, Biodegradable biomaterials, Skin repair), Wikipedia
  2. Stainless steel, Wikipedia
  3. Synthetic biodegradable polymer, Wikipedia

The frameworks of Biomaterials

Each framework is a way of working the field has used: when it held, and the question it answers.

  1. 1940-1980

    Inert biomaterials

    How can a material be ignored by the body?

    Fly to its tower in Nousfarer

  2. 1965-Present

    Protein adsorption

    What does the body see first at a surface?

    Fly to its tower in Nousfarer

  3. 1970-1995
  4. 1970-Present

    Synthetic biodegradable polymer

    How can a material dissolve safely in the body?

    Fly to its tower in Nousfarer

  5. 1971-Present

    Bioactive materials

    How can a material bond directly to living tissue?

    Fly to its tower in Nousfarer

  6. 1988-Present

    Tissue engineering

    How can we grow new tissue instead of replacing it?

    Fly to its tower in Nousfarer

  7. 2000-Present
  8. 2000-Present

    Biodegradable metals

    Can a metal implant corrode away safely?

    Fly to its tower in Nousfarer

  9. 2010-Present

    Immunomodulatory biomaterials

    How can a material steer the immune response?

    Fly to its tower in Nousfarer

How the ideas connect

Each arrow runs from an earlier idea to the later one it shaped. The list below says what passed between them.

Inert biomaterialsProtein adsorptionRetrieval and failure analysisSynthetic biodegradable polymerBioactive materialsTissue engineeringAdditive manufacturing of biomaterialsBiodegradable metalsImmunomodulatory biomaterials

Beyond the field

Where Biomaterials's ideas came from in other fields, and what they led to there: the strongest 12 of 29 links.

A city in Nousfarer: a red-carpeted stair climbing terraces to a crowned tower on an acropolis, more towers round it, forest and snowy mountains beyond.
A city in Nousfarer, the game played in the browser.

Biomaterials is a planet in Nousfarer

Its city has a tower for each of these 9 frameworks. Land, walk in, and climb one concept at a time.

Land on Biomaterials

Related fields

Fields its ideas are linked to

More in Materials Science

See where Biomaterials sits on the Map of Human Knowledge